# Biomarker-guided selection of potent tumor-specific TCRs

T cells are central to anti-tumor immunity, but only a minority of tumor-specific TCRs provides strong and durable protection. Today, finding such high-functionality TCRs requires complex functional screens and often invasive tumor sampling. A robust, blood-based way to pinpoint the most protective TCRs would significantly accelerate development, de-risk selection and reduce cost of personalized T cell therapies and related diagnostics.



## PD-1–based enrichment of high-affinity tumor TCRs

IP RIGHTS
PCT filed, US and EP pending
2023

The technology decodes a "success signature" of tumor-specific T cells: high PD-1 surface levels plus defined activation-gene expression in peripheral blood reliably mark TCRs with superior functional avidity. This enables targeted isolation, ranking and engineering of the most potent tumor-reactive TCRs without TILs or labor-intensive empirical screening.

01 Easy, cost-efficient enrichment of highly functional tumor-specific TCRs from peripheral blood

02 PD-1 and activation-gene markers as a biomarker panel for TCR discovery assays

03 Applicable to T-cell therapy development and diagnostics

04 Broadly applicable across solid tumors and adaptable to diverse neoantigen targets




**Extratumoral activation signatures serve as a biomarker for identification of high-functionality TCRs of tumor-specific T cells**

## CHALLENGE

Tumor antigen-specific T cells are central to cancer control and are already exploited in TCR-engineered T-cell therapies and TIL products. However, only a fraction of tumor-reactive TCRs are truly protective. Because the TCR repertoire is highly dynamic across tissues and over time, and functional avidity is difficult to measure, identifying high-functionality TCRs remains complex, resource-intensive and a key bottleneck for therapeutic and diagnostic development.

## INNOVATION

The invention provides a biomarker-based system to identify highly functional tumor-specific TCRs directly from peripheral blood. Single-cell sequencing of neoantigen-specific T cells combined with CRISPR-Cas9 TCR reexpression shows that TCRs with superior protective capacity are enriched in T cells with signatures of recent activation. PD-1 surface expression and defined activation-gene markers form a practical, scalable framework to enrich, rank and prioritize such TCRs for therapeutic and diagnostic use.




**01** Basic principles observed · **02** Technology concept formulated · **03** Experimental proof of concept · **04** Technology validated in lab · **05** Technology validated in relevant environment · **06** Technology demonstrated in relevant environment · **07** System prototype demonstrated in operational environment · **08** System complete and qualified

BayPAT

Innovation from Research & Science – BayPAT markets inventions on behalf of the Bavarian universities and universities of applied sciences.

An invention of **Technical University of Munich**

Technische Universität München

As one of the largest technology transfer offices in Germany, BayPAT evaluates and commercializes innovations from 28 research institutions. With our extensive experience and expertise in patenting and licensing technologies and our comprehensive range of services, we are your partner of choice. For more information visit www.baypat.de

**Bayerische Patentallianz GmbH**
**Dr. Linda Keil**
lkeil@baypat.de
+49 (0)89 5480177-30
Prinzregentenstr. 52
80538 München